Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Avacta Group plc ( (GB:AVCT) ).
Avacta Group plc reported new data at the American Association for Cancer Research 2026 meeting that bolster the profile of its pre|CISION oncology delivery platform and its second clinical candidate, AVA6103. Updated preclinical analyses show AVA6103, a FAP-activated exatecan peptide-drug conjugate now in a Phase 1 trial, demonstrates strong antitumor activity even in models with low FAP expression and achieves higher tumor exposure, faster penetration, and a threefold better tumor selectivity index than the antibody-drug conjugate Enhertu in comparative modelling.
The company also unveiled first in vivo pharmacokinetic and efficacy results for its dual-payload program AVA6207, which uses pre|CISION to co-deliver a topoisomerase I inhibitor and a DNA damage repair inhibitor to overcome key mechanisms of drug resistance. In patient-derived xenograft models, AVA6207 showed robust, tumor-selective release of both payloads and superior activity to Enhertu in HER2-positive gastric cancer with low FAP levels, underscoring the platform’s potential to widen the therapeutic window and support new combination therapies for cancer.
Spark’s Take on AVCT Stock
According to Spark, TipRanks’ AI Analyst, AVCT is a Neutral.
Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on AVCT stock, click here.
More about Avacta Group plc
Avacta Therapeutics, a unit of Avacta Group plc, is a clinical-stage biopharmaceutical company focused on oncology. It develops pre|CISION, a fibroblast activation protein (FAP)-activated peptide-drug conjugate platform designed to concentrate highly potent chemotherapeutic payloads in the tumor microenvironment while limiting systemic exposure and toxicity. Its pipeline includes AVA6000, a FAP-enabled version of doxorubicin, and AVA6103, which applies the same targeted delivery approach to exatecan for hard-to-treat solid tumors.
Average Trading Volume: 1,867,051
Technical Sentiment Signal: Hold
Current Market Cap: £323.7M
For a thorough assessment of AVCT stock, go to TipRanks’ Stock Analysis page.